These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 17851109

  • 1. Fragment-based screening using X-ray crystallography and NMR spectroscopy.
    Jhoti H, Cleasby A, Verdonk M, Williams G.
    Curr Opin Chem Biol; 2007 Oct; 11(5):485-93. PubMed ID: 17851109
    [Abstract] [Full Text] [Related]

  • 2. Fragment-based lead discovery: a chemical update.
    Erlanson DA.
    Curr Opin Biotechnol; 2006 Dec; 17(6):643-52. PubMed ID: 17084612
    [Abstract] [Full Text] [Related]

  • 3. Fragment-based activity space: smaller is better.
    Hesterkamp T, Whittaker M.
    Curr Opin Chem Biol; 2008 Jun; 12(3):260-8. PubMed ID: 18316043
    [Abstract] [Full Text] [Related]

  • 4. Structure-guided fragment screening for lead discovery.
    Verdonk ML, Hartshorn MJ.
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):404-10. PubMed ID: 15338949
    [Abstract] [Full Text] [Related]

  • 5. A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions.
    Huber W.
    J Mol Recognit; 2005 Jul; 18(4):273-81. PubMed ID: 15997470
    [Abstract] [Full Text] [Related]

  • 6. Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design.
    Tsao DH, Sutherland AG, Jennings LD, Li Y, Rush TS, Alvarez JC, Ding W, Dushin EG, Dushin RG, Haney SA, Kenny CH, Malakian AK, Nilakantan R, Mosyak L.
    Bioorg Med Chem; 2006 Dec 01; 14(23):7953-61. PubMed ID: 16919463
    [Abstract] [Full Text] [Related]

  • 7. Fragonomics: fragment-based drug discovery.
    Zartler ER, Shapiro MJ.
    Curr Opin Chem Biol; 2005 Aug 01; 9(4):366-70. PubMed ID: 15925537
    [Abstract] [Full Text] [Related]

  • 8. NMR fragment screening: tackling protein-protein interaction targets.
    Schade M, Oschkinat H.
    Curr Opin Drug Discov Devel; 2005 May 01; 8(3):365-73. PubMed ID: 15892252
    [Abstract] [Full Text] [Related]

  • 9. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T.
    Methods Enzymol; 2011 May 01; 493():469-85. PubMed ID: 21371602
    [Abstract] [Full Text] [Related]

  • 10. Lead generation and examples opinion regarding how to follow up hits.
    Orita M, Ohno K, Warizaya M, Amano Y, Niimi T.
    Methods Enzymol; 2011 May 01; 493():383-419. PubMed ID: 21371599
    [Abstract] [Full Text] [Related]

  • 11. Solid-state NMR spectroscopy as a tool for drug design: from membrane-embedded targets to amyloid fibrils.
    Middleton DA.
    Biochem Soc Trans; 2007 Nov 01; 35(Pt 5):985-90. PubMed ID: 17956260
    [Abstract] [Full Text] [Related]

  • 12. Crystallography, NMR and virtual screening: integrated tools for drug discovery.
    Muchmore SW, Hajduk PJ.
    Curr Opin Drug Discov Devel; 2003 Jul 01; 6(4):544-9. PubMed ID: 12951817
    [Abstract] [Full Text] [Related]

  • 13. Ligand-target interaction-based weighting of substructures for virtual screening.
    Crisman TJ, Sisay MT, Bajorath J.
    J Chem Inf Model; 2008 Oct 01; 48(10):1955-64. PubMed ID: 18821751
    [Abstract] [Full Text] [Related]

  • 14. Practical aspects of NMR-based fragment screening.
    Lepre CA.
    Methods Enzymol; 2011 Oct 01; 493():219-39. PubMed ID: 21371593
    [Abstract] [Full Text] [Related]

  • 15. A structure-based strategy to identify new molecular scaffolds targeting the bacterial ribosomal A-site.
    Foloppe N, Chen IJ, Davis B, Hold A, Morley D, Howes R.
    Bioorg Med Chem; 2004 Mar 01; 12(5):935-47. PubMed ID: 14980606
    [Abstract] [Full Text] [Related]

  • 16. Characterization of protein-ligand interaction sites using experimental and computational methods.
    Vajda S, Guarnieri F.
    Curr Opin Drug Discov Devel; 2006 May 01; 9(3):354-62. PubMed ID: 16729732
    [Abstract] [Full Text] [Related]

  • 17. High-throughput X-ray crystallography for drug discovery.
    Blundell TL, Patel S.
    Curr Opin Pharmacol; 2004 Oct 01; 4(5):490-6. PubMed ID: 15351354
    [Abstract] [Full Text] [Related]

  • 18. Fragment screening purely with protein crystallography.
    Spurlino JC.
    Methods Enzymol; 2011 Oct 01; 493():321-56. PubMed ID: 21371597
    [Abstract] [Full Text] [Related]

  • 19. Competition STD NMR for the detection of high-affinity ligands and NMR-based screening.
    Wang YS, Liu D, Wyss DF.
    Magn Reson Chem; 2004 Jun 01; 42(6):485-9. PubMed ID: 15137040
    [Abstract] [Full Text] [Related]

  • 20. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
    Giannetti AM.
    Methods Enzymol; 2011 Jun 01; 493():169-218. PubMed ID: 21371592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.